Pure Play Orthobiologics Will Expand US Healthcare Access

Key Takeaways

• Strategic shift to orthobiologics boosts growth and operational efficiency, enhancing future revenue and sustaining high net margins.
  
• U.S. market expansion and distinctive product benefits position OssDsign for significant market share and increased adoption.
  
• Heavy reliance on limited customers, high competition, and regulatory risks could create revenue volatility and potential cash flow challenges.

Catalysts

Designs, manufactures, and sells implants and material technology for bone regeneration in Sweden, Germany, the United States, the United Kingdom, rest of Europe, and internationally.

• The strategic shift to a pure-play orthobiologics company has proven highly successful, as evidenced by over 100% year-over-year growth. Continued operational efficiency improvements and scalability are expected to drive future revenue growth.
  
• The company's gross margin increased to 95.4% for the full year, up from 74.6% in 2023, signaling improved production efficiencies that are likely to sustain high net margins moving forward.
  
• OssDsign's significant investment in building a robust repository of clinical evidence through more than 10 clinical and preclinical white papers enhances its value proposition, which could drive increased adoption and revenue.
  
• The expansion into the U.S. market, including the signing of a large GPO contract and broad access to hospitals and surgical centers, positions OssDsign favorably to capture significant market share, boosting future earnings.
  
• OssDsign Catalyst’s unique capabilities, such as exceptional intraoperative handling qualities and dual pathway bone formation, provide distinct competitive advantages likely to lead to increased sales and market penetration.

OssDsign Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming OssDsign's revenue will grow by 26.2% annually over the next 3 years.
• Analysts assume that profit margins will increase from -28.3% today to 5.0% in 3 years time.
• Analysts expect earnings to reach SEK 18.1 million (and earnings per share of SEK 0.17) by about April 2029, up from -SEK 51.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting SEK47.0 million in earnings, and the most bearish expecting SEK-5.6 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 113.4x on those 2029 earnings, up from -8.9x today. This future PE is greater than the current PE for the SE Medical Equipment industry at 26.7x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 5.99%, as per the Simply Wall St company report.

Risks

• The company relies heavily on a limited number of customers and specific orders for growth, indicated by the mention of one-off orders contributing to past growth, which could create revenue volatility. (Revenue)
  
• The presence of high competition in the orthobiologics market suggests potential difficulty in maintaining high growth and market share, impacting future revenue projections. (Revenue)
  
• Increased provisions related to royalty payments indicate the possibility of higher-than-expected operational costs, which could affect profitability. (Net Margins)
  
• Despite reaching its targeted revenue run rate, the company is still cash flow negative, indicating challenges in achieving cash flow positivity and potential liquidity issues. (Earnings)
  
• OssDsign’s reliance on FDA-clearance for future market pursuits suggests potential regulatory risks, which could affect the speed and success of U.S. market expansion. (Revenue)

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of SEK12.75 for OssDsign based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK15.0, and the most bearish reporting a price target of just SEK10.5.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be SEK362.2 million, earnings will come to SEK18.1 million, and it would be trading on a PE ratio of 113.4x, assuming you use a discount rate of 6.0%.
• Given the current share price of SEK4.09, the analyst price target of SEK12.75 is 67.9% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.